ReviewFrontiers in medicine2022
From fecal microbiota transplantation toward next-generation beneficial microbes: The case of
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- Article
- Key Safety Criteria for Novel Microbial Food Ingredients: A Comparative Analysis of International Regulatory Frameworks.Journal of microbiology and biotechnology · 2026Review
- Topological characteristics and longitudinal dynamics of co-abundance networks involving beneficial commensal bacteria in the pig gut microbiome and its association with average daily gain.Frontiers in microbiology · 2026Article
- Anorexia nervosa symptoms are induced after specific gut microbiota dysbiosis transfer in germ-free mice.Gut microbes · 2025Article
- Membrane vesicles produced by next-generation probiotics from the gut as innovative tools for human health.Gut microbes · 2025Review
- Butyrate-producing gut bacteriumThe European respiratory journal · 2025Article
- Triacetin and a Mushroom Blend Restore Butyrate Production by IBS Microbiomes Ex Vivo, Thus Promoting Barrier Integrity.International journal of molecular sciences · 2025Article
- The Future of Microbiome Therapeutics.Drugs · 2025Review
- Changes in the intestinal microbiota of broiler chicken induced by dietary supplementation of the diatomite-bentonite mixture.BMC veterinary research · 2025Article
- Article
- Microbial diversity and composition in the gut microbiome of patients during systemic inflammatory response syndrome: can we use gut bacteria as potential biomarkers to characterize sepsis?Frontiers in cellular and infection microbiology · 2025Article
- Evaluation of kefir consumption on gut microbial diversity in a healthy young population using full-length 16S rRNA sequencing.Frontiers in microbiology · 2025Article
- Insights into the gut microbiome of vitiligo patients from India.BMC microbiology · 2024Article
- OraliScience · 2024Article
- Gut Microbiota and Clinical Manifestations in Thai Pediatric Patients with Attention-Deficit Hyperactivity Disorder.Journal of personalized medicine · 2024Article
- Non-lactic acid bacteria probiotics isolated from intestine or various circumstances.Food science and biotechnology · 2024Review
- The gut microbiome modulates the impact of Anaerobutyricum soehngenii supplementation on glucose homeostasis in mice.Research square · 2024Article
- Article
- Short term supplementation with cranberry extract modulates gut microbiota in human and displays a bifidogenic effect.NPJ biofilms and microbiomes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The commensal gut microbiota is important for human health and well-being whereas deviations of the gut microbiota have been associated with a multitude of diseases. Restoration of a balanced and diverse microbiota by fecal microbiota transplantation (FMT) has emerged as a potential treatment strategy and promising tool to study causality of the microbiota in disease pathogenesis. However, FMT comes with logistical challenges and potential safety risks, such as the transfer of pathogenic microorganisms, undesired phenotypes or an increased risk of developing disease later in life. Therefore, a more controlled, personalized mixture of cultured beneficial microbes might prove a better alternative. Most of these beneficial microbes will be endogenous commensals to the host without a long history of safe and beneficial use and are therefore commonly referred to as next-generation probiotics (NGP) or live biotherapeutic products (LBP). Following a previous FMT study within our group, the commensal butyrate producer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.